Accès ouvert
2025
article
OpenAlex
Nicholas P. Clarke, Peter Thornton, Valérie Reader, Nicola A. Lindsay et autres
BACKGROUND: Inhibition of Nod-like receptor protein 3 (NLRP3) inflammasome within the central nervous system (CNS) is a promising therapeutic target for the treatment of Parkinson's disease (PD). OBJECTIVES: This phase 1b open-label study was conducted in elderly healthy volunteers (HV) and PD …
gb
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Ryan L. Crass, Brandon A. Smith, Sven Adriaens, Sunny Hong Chapel et autres
Paroxysmal nocturnal hemoglobinuria is a rare blood disorder characterized by life-threatening hemolysis and thrombosis. Complement C5 inhibitor therapy improves symptoms and life prognosis; however, it can result in insufficient hemolysis control, with residual intravascular hemolysis and extravascular hemolysis in some patients. Pegcetacoplan, …
us, se
(code pays fourni par la source)
Accès ouvert
2021
article
OpenAlex
Mohamed Farouk Chughlay, Myriam El Gaaloul, Cristina Donini, Brice Campo et autres
P218 is a highly selective dihydrofolate reductase inhibitor with potent in vitro activity against pyrimethamine-resistant Plasmodium falciparum. This single-center, randomized, double-blind, placebo-controlled phase Ib study evaluated P218 safety, pharmacokinetics, and chemoprotective efficacy in a P. falciparum sporozoite (PfSPZ) volunteer infection study (VIS). …
ch, be, es
(code pays fourni par la source)
Accès ouvert
2020
article
OpenAlex
Tadeusz Robak, Maciej Kaźmierczak, Isidro Jarque, Vasile Musteata et autres
Primary immune thrombocytopenia (ITP) is a predominantly immunoglobulin G (IgG)-autoantibody-mediated disease characterized by isolated thrombocytopenia. Rozanolixizumab, a subcutaneously infused humanized monoclonal anti-neonatal Fc receptor (FcRn) antibody, reduced serum IgG in healthy volunteers. In this phase 2, multicenter, open-label study, patients with persistent/chronic …
pl, es, gb, de, us
(code pays fourni par la source)
Accès ouvert
2020
article
OpenAlex
Mohamed Farouk Chughlay, Emilie Rossignol, Cristina Donini, Myriam El Gaaloul et autres
Aims This first‐in‐human clinical trial of P218, a novel dihydrofolate reductase inhibitor antimalarial candidate, assessed safety, tolerability, pharmacokinetics and food effects in healthy subjects. Methods The study consisted of two parts. Part A was a double‐blind, randomized, placebo‐controlled, parallel group, ascending dose …
ch, au, us, gb
(code pays fourni par la source)
Accès ouvert
2020
article
OpenAlex
Phumla Sinxadi, Cristina Donini, Hilary Johnstone, Grant Langdon et autres
induced blood-stage malaria (IBSM) model. Due to the high pharmacokinetic variability with the powder-in-bottle formulation used in both of these studies, a third study was undertaken to select a tablet formulation of MMV390048 to take forward into future studies. MMV390048 was generally …
Afrique du Sud, ch, au
(code pays fourni par la source)
Accès ouvert
2019
conference-abstract
OpenAlex
Tadeusz Robak, Maciej Kaźmierczak, Isidro Jarque, Vasile Musteata et autres
Introduction Rozanolixizumab targets the human neonatal Fc receptor (FcRn). By blocking IgG recycling, this first-in-class subcutaneously (SC) infused monoclonal antibody aims to improve the course of immunoglobulin G (IgG)-mediated autoimmune diseases by reducing pathogenic autoantibody levels. We report the completed Phase II, …
pl, es, gb, de, us
(code pays fourni par la source)
2017
article
OpenAlex
Peter C. Kiessling, Rocío Lledó‐García, Shikiko Watanabe, Grant Langdon et autres
= 1)]. Rozanolixizumab pharmacokinetics demonstrated nonlinear increases with dose. There were sustained dose-dependent reductions in serum IgG concentrations (IV and SC rozanolixizumab). These data provide clinical evidence for the therapeutic potential of rozanolixizumab.
de, gb, be
(code pays fourni par la source)
2015
conference-abstract
OpenAlex
Spencer I. Danto, Grant Langdon, Negin Shojaee, Jared L. Christensen et autres
COPD is characterized by inflammation and lung function decline. p38 MAPK inhibition may be an anti-inflammatory therapeutic approach to COPD. The efficacy and safety of PH-797804 (PH), a potent, selective oral p38 inhibitor, was tested in three studies including patients with GOLD …
us
(code pays fourni par la source)
2013
conference-abstract
OpenAlex
Robert Fogel, Kathleen M. Shields, Jared L. Christensen, Jakob Ribbing et autres
Despite the recognized role of pulmonary inflammation in the pathogenesis of the disease, anti-inflammatory drugs have demonstrated only limited efficacy in COPD. Inhibitors of the p38 MAP kinase may have an important role in treating inflammation in COPD. Here we extend previous …
us
(code pays fourni par la source)
2013
article
OpenAlex
Manoli Vourvahis, John D. Davis, Grant Langdon, Gary R. Layton et autres
BACKGROUND: To investigate pharmacokinetic interactions associated with coadministration of lersivirine with zidovudine, tenofovir disoproxil fumarate (DF)/emtricitabine (Truvada(®)) or abacavir/lamivudine (Epzicom(®)/Kivexa(®)). METHODS: Three Phase I, open, crossover studies with two (studies 1 and 3) or three (study 2) treatment periods were conducted in …
us, gb
(code pays fourni par la source)
2012
article
OpenAlex
Manoli Vourvahis, Grant Langdon, Gary R. Layton, Robert R. LaBadie et autres
OBJECTIVE: Lersivirine (UK-453,061) is a next-generation nonnucleoside reverse transcriptase inhibitor, active against wild-type HIV-1 and several nonnucleoside reverse transcriptase inhibitor-resistant strains. Four studies evaluated the pharmacokinetic (PK) interactions between lersivirine and various HIV-1 protease inhibitors. METHODS: Four phase I trials were conducted …
us, gb, be
(code pays fourni par la source)